TriSalus Life Sciences, Inc. (TLSI)
4.97
-0.17
(-3.31%)
USD |
NASDAQ |
Sep 03, 15:33
TriSalus Life Sciences Enterprise Value : 304.09M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 304.09M |
| September 01, 2026 | 305.94M |
| August 31, 2026 | 292.41M |
| August 28, 2026 | 285.04M |
| August 27, 2026 | 291.18M |
| August 26, 2026 | 291.18M |
| August 25, 2026 | 297.33M |
| August 24, 2026 | 302.25M |
| August 21, 2026 | 312.08M |
| August 20, 2026 | 309.62M |
| August 19, 2026 | 325.61M |
| August 18, 2026 | 320.07M |
| August 17, 2026 | 312.08M |
| August 14, 2026 | 312.08M |
| August 13, 2026 | 334.21M |
| August 12, 2026 | 339.13M |
| August 11, 2026 | 340.97M |
| August 10, 2026 | 331.14M |
| August 07, 2026 | 332.98M |
| August 06, 2026 | 287.50M |
| August 05, 2026 | 272.13M |
| August 04, 2026 | 279.50M |
| August 03, 2026 | 280.12M |
| July 31, 2026 | 267.21M |
| July 30, 2026 | 268.44M |
| Date | Value |
|---|---|
| July 29, 2026 | 257.37M |
| July 28, 2026 | 254.30M |
| July 27, 2026 | 253.69M |
| July 24, 2026 | 247.54M |
| July 23, 2026 | 250.61M |
| July 22, 2026 | 248.77M |
| July 21, 2026 | 254.92M |
| July 20, 2026 | 253.07M |
| July 17, 2026 | 251.84M |
| July 16, 2026 | 256.15M |
| July 15, 2026 | 240.16M |
| July 14, 2026 | 236.48M |
| July 13, 2026 | 248.15M |
| July 10, 2026 | 242.62M |
| July 09, 2026 | 227.25M |
| July 08, 2026 | 214.35M |
| July 07, 2026 | 238.32M |
| July 06, 2026 | 253.07M |
| July 02, 2026 | 276.43M |
| July 01, 2026 | 262.29M |
| June 30, 2026 | 267.82M |
| June 29, 2026 | 269.04M |
| June 26, 2026 | 268.42M |
| June 25, 2026 | 246.31M |
| June 24, 2026 | 233.42M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.097B |
| Alnylam Pharmaceuticals, Inc. | 35.44B |
| Anika Therapeutics, Inc. | 275.24M |
| Savara, Inc. | 978.85M |
| Vericel Corp. | 2.024B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.187M |
| Revenue (Quarterly) | 11.41M |
| Total Expenses (Quarterly) | 20.59M |
| EPS Diluted (Quarterly) | -0.1576 |
| Gross Profit Margin (Quarterly) | 86.78% |
| Profit Margin (Quarterly) | -80.54% |
| Earnings Yield | -26.06% |
| Normalized Earnings Yield | -27.80 |